Life Sciences Archive » October, 2023

Life Sciences - October, 2023

365 articles

• New Jersey Gov. Fumes As Orsted Drops Wind Farm Projects
• Conn. AG Presses 23andMe Over User Data Breach
• Here's What's To Come In Fight Over Apple Watch Import Ban
• Mich. AG Says Christian Clinic Can't Bolster Record In Appeal
• 6th Circ. Asked To Step Into Opioid Special Master Row
• Dem. Sens. Urge Biden Admin. To Cover OTC Birth Control
• Weight Loss Drug Developer Files For Liquidation
• 3rd Circ. Presses For Evidence In Merck Shingles Vax Suit
• ITC Won't Review Decision In Biomolecular Patent Fight
• GoodRx Privacy Deal Sets Milberg Fees At Up To $4.5M
• Munger Tolles Fights DQ Bid In GenapSys' Paul Hastings Suit
• What To Know About The White House's Sweeping AI Directive
• PCBs Didn't Cause Brain Damage In Wash. Case, Jury Told
• 9th Circ. Reopens Providers' Challenge To Ariz. Abortion Law
• Vidal Urges Input On Invalidating Patents For Misconduct
• Justices Refuse To Take Up Maine Hospital Workers' Vax Suit
• Eli Lilly Tries To Nix Claims In Mounjaro Failure-To-Warn Suit
• 3rd Circ. Says Janssen Can't Appeal DTSA Seizure Order
• Co., CEO Who Defended 'Pharma Bro' Reach $50M FCA Deal
• Medical School Supervisors Accused Of 'Conspiratorial Cabal'
• ESG Around The World: The UK
• Microscope Equipment Maker's Trade Secrets Suit Narrowed
• Boeing Opinion Strikes Blow Against Overpayment Theory
• Health Systems Say Meta Data-Sharing Suit Lacks Substance
• Tips For Litigating Against Pro Se Parties In Complex Disputes
• Gene Therapy-Focused Lexeo Therapeutics Eyes $126M IPO
• High Court Asks Apple To Chime In On Time Limit At PTAB
• Rush University Hospital Sued Over Worker Fingerprint Scans
• Are Justices Split 3-3-3? New Term Is Already Offering Clues
• Pharmacy Wants Out Of Eli Lilly Diabetes Drug Suit
• 3M Looks To Pause Warming Device Defense Coverage Row
• 6th Circ. Urged To Preserve Faith-Based Hiring Exemption
• Texas Pharmacy Owner Convicted In $55M Fraud Scheme
• What Pharma Cos. Must Know About FDA Off-Label Guidance
• 9th Circ. Kicks Psilocybin Rescheduling Petition To DEA
• Bayer, Janssen Sue Taro Over Xarelto Generic
• 3M Polluted Delaware With PFAS, Hid Harm, State AG Alleges
• Biotech Firm Rips 'Time-Worn Cudgel,' Wants Attys Punished
• Warrants In Pfizer Insider-Trading Case Fair Game, Feds Say
• Gilead Judge Leery Of Drug Buyers' New Antitrust Trial Bid
• Amyris Creditor Claims Doerr Schemed To Seize IP
• 1st Circ. OKs Immunity To Officials In Workers' COVID-19 Suit
• Satanic Temple Can't Challenge Indiana Abortion Ban
• How Mike Johnson Stands On 3 Key Health Care Policy Issues
• Apple Gets PTAB To Ax Bulk Of AliveCor Heart Monitor Claims
• Pear Therapeutics Wants More Time To File Ch. 11 Plan
• Monsanto Spinoff's Expert Says PCB Plaintiffs Look Healthy
• Emcure Again Looks To Toss HDT's $950M Trade Secrets Suit
• Laser Co. Ends TM Suit Over Rival's Celebrity Laser Treatment
• Veterinary Stem Cell Patent Case Settles Days Before Trial
• Ex-Stimwave Director Wants Company To Pay His Legal Bills
• ITC Bans Apple Watch Imports In Masimo Patent Case
• Sofinnova Partners Closes $200M Digital Medicine Fund
• It's Time To Prescribe Frameworks For AI-Driven Health Care
• Mass. Biotech Clinches $92M Series A Funding Round
• Cannabis Operators Say Federal Ban Is Unconstitutional
• Bayer Fights Bid To Toss $12M Benzene Contamination Suit
• The Murky World Of IP Protection For Gene-Edited Plants
• Pa. Court Inks $15M Judgment Against Defunct Cannabis Co.
• Novartis Should Face Gender Bias Case, Judge Says
• Shutts & Bowen Adds Leading Anti-Abortion Atty To Its Ranks
• Penile Implant Doc Deserves $46M After Trial Win, Judge Told
• US Trustee Balks At 5% Breakup Fee In Zymergen Bid
• Ecolab, DuBois Dueling Bids Mostly Rejected In Patent Row
• First Nations Group Asks High Court To Nix Sackler Releases
• PTAB Largely Invalidates Patent In UV Sanitation Fight
• FDA Plans Tighter Scrutiny Of Off-Label Data Sent To Doctors
• 6th Circ. Eyes Reviving Little Debbie Maker's ERISA Fight
• Novartis Sues Takeda To Address Possible IP Theft
• FTC, Illumina Say EU Unwinding Order Won't Impact Appeal
• Drug Cos. Question When Reissued Patent Is Actually Issued
• FDA Will Review AstraZeneca Nasal Spray Flu Vaccine
• New Initiatives Will Advance Corporate Biodiversity Reporting
• 'Concerning Error' Dooms SEC Case Against Zicam Inventor
• FTC Halts Marketing Of 'Invisible' Anti-COVID Mask
• Medical Lab Co. Wants Managers Out Of Wage Dispute
• Amyris Noteholders Tag Doerr In Ch. 11 Discovery Push
• Alternative Patents Would Solve Many Inventor Woes
• Class Action Defense: Don't Give Up On Bristol-Myers Squibb
• Ga. Doc Appeals $27.5M Judgment In False Billing Scheme
• Biden's Pick For NIH Director Advances With GOP Support
• Pro Bono Work Is Powerful Self-Help For Attorneys
• Judge Rips 'Nonsensical' Class Action Over P&G Supplement
• Monsanto Resolves Claims It Excluded Farmworker From Deal
• Kristen Bell's Baby Co. Gets Interim OK For $47M DIP In Ch. 11
• Dialysis Cos. Settle Double-Billing Allegations For $9.5M
• Patent Office Raises IP Questions For Tribes
• Sotera Solidifies Masimo Patent Wipeout With Fed. Circ. Win
• Startups Take Lead On Some COVID-19 Patents
• HHS 'Coerces' Abortion Stance With Title X Loss, Tenn. Says
• Insurer Used 'Legal Loopholes' To Avoid Payments, Court Told
• FDA Proposals Clarify Rules For Devices With Predicates
• State Regs Sow Discord Between Cannabis, Hemp Industries
• Gunderson Dettmer Advises OrbiMed In $4.3B Fund Round
• Med-Tech Co. UpHealth And 6 Units Get OK For Joint Ch. 11
• Malpractice Row Is 'Groundhog Day,' Texas Justices Told
• Playing In A Rock Cover Band Makes Me A Better Lawyer
• AI May Help Patent Applicants With Functional Claiming
• Ga. Abortion Ban Not Voided By Roe, State Justices Rule
• Wyrick Robbins Guiding Citius Oncology Unit In SPAC Merger
• Roche And Biogen Settle Patent Row Over Arthritis Biosimilar
• Boston Scientific Valve Recall Sparks Shareholder's Del. Suit
• HHS Says Texas' Abortion Pill Guidance Fight Is Moot
• Kansas Judge Nixes Product-Liability Suit Over Huffing Death
• Medicare Drug Price Talks Boon For Public Health, Court Told
• Flint Expert Barred From Discussing Lead's Effect On Fetuses
• Inventors Face 'Tough Love' From PTAB Critics On Politics
• 10x Dodges Inter Partes Review In Split PTAB Decision
• How Int'l Regulatory Collabs Can Expedite Pharma Approvals
• 10 Charged With $20M Black Market HIV Drug Fraud Scheme
• How Executives' Deposition Standards Can Differ
• High Court Told Purdue's Ch. 11 Liability Waiver Is Legal
• Goodwin Adds Ropes & Gray Life Sciences Pro In China, Calif.
• Catching Up With Delaware's Chancery Court
• The Pop Culture Docket: Judge Espinosa On 'Lincoln Lawyer'
• 1315 Capital Lands $500M Across 2 Health Care Funds
• Icahn Says $8B Illumina-Grail Deal Caused Millions In Losses
• Calif. GHG Disclosure Law Will Affect Companies Worldwide
• Kristen Bell's Hollywood Diaper Co. Hello Bello Hits Ch. 11
• 23andMe Exposed Ashkenazi Jews' Data In Breach, Suit Says
• SG Wants Ch. 11 Carve-Out Cases Stalled Until Purdue Ruling
• DEA Process For Drug Rescheduling Unlawful, 9th Circ. Hears
• Market Headwinds And Geopolitical Risks Muddle IPO Plans
• Questions Linger After FDA's Lab-Developed Tests Proposal
• Lessons For Biosimilar And Biologic Antitrust Litigation
• Supplement Co. Owners Must Post Bond To Stay TM Penalty
• Crowell Says Walgreens Is 'Sandbagging' In Humana Suit
• Health Care Tech Co.'s Atty Moves Firing Suit To NY Fed. Court
• Balancing Justice And Accountability In Opioid Bankruptcies
• MVP: Winston & Strawn's George Lombardi
• UK Litigation Roundup: Here's What You Missed In London
• Gateley Hires Clifford Chance Duo To Head Arbitration Team
• 4 Firms Guide French Biotech Firm Abivax's $236M US IPO
• European Commission Issues 1st Ever Pharma Cartel Fine
• Taxation With Representation: Skadden, Cravath, Latham
• Altria Unit Says Dozens Of Vape Makers Sell Illegal Products
• SEC Says Jury Should Hear First 'Shadow Trading' Case
• 9th Circ. To Hear Args In Psilocybin Rescheduling Challenge
• House Panel Mulls Medicare Payment, Prior Authorization Bills
• Petition Watch: Abortion Protests, Workers' Comp & Sanctions
• IP Forecast: NXP-Impinj Patent Battle Heads To Waco
• FDA Issues New COVID Vaccine Development Guidance
• Bankrupt Rite Aid's New Directors To Earn $50K Per Month
• 5th Circ. Asks Illumina, FTC For Update On EU Order's Impact
• Biotech Co. Exec Gets 8 Years Over Blood Test Fraud
• Biden Admin Plans Stricter Toxic Chemical Evaluations
• PFAS-Tainted Water Sold By Conn. Utilities, Customers Allege
• FCA Suits Anticipated As COVID Criminal Cases Wrap Up
• How To Navigate The FTC's New Private Equity Frontier
• Bovine Breeding Co. Wins Remand After PTAB Loss
• Calif. Man Admits Guilt In Pfizer Insider Trading Scheme
• 'Unacceptable Gamesmanship' Gets Calif. IP Atty Disbarred
• Newman Suspension Shows Need For Judicial Reform
• Faegre Drinker Adds Attys With Health Care Experience
• Rite Aid Cites 'Substantial Doubt' It Can Stay In Business
• MVP: Sullivan & Cromwell's Matt Hurd
• Novartis Airs Mea Culpa As 2nd Circ. Probes Kickback Theory
• Calif. Embraces Bold New Climate, Consumer, Labor Laws
• Natera Hid Prenatal Test Authorization Scheme, Investor Says
• Trans Adults, Minors Get Class Cert. In Fla. Health Care Fight
• Philips Medical Is Told To Pay $2.5M Treble Damages To Rival
• 6 Lewis Brisbois Attys Join Wilson Elser In Pacific NW Growth
• Doctor Staffing Cos. To Pay $4.3M To End Mich. FCA Suits
• Ohio Broker Gets 10 Years For Medical Lab Investment Scam
• Judge Invites Tipster To Fix Medicaid Rebate FCA Suit
• Sorrento Cleared For $20M JV Sale In Ch. 11 Case
• J&J Floats 3rd Bankruptcy For Talc Claims On Earnings Call
• Teva Loses Challenge Of €60M Pay-For-Delay Fine
• ArcherDX Renews Bid To Ax $19M Patent Verdict
• ITC Has Few Answers On How IP Constrains COVID Treatments
• JPML Should Say If Foam Co. Coverage Suit Belongs In MDL
• Ex-Navy Officer Gets 2.5 Years For $2M Insurance Fraud
• An Overview Of Congress' Proposed Drug Shortage Solutions
• McCarter & English Urges Judge To Reject Ex-Client's Retrial
• 5th Circ. Upends Louisiana Judge's Forced-Medication Ruling
• Counsel For J&J Talc Unit Ch. 11 Committee Fight For Fees
• Regeneron Kickback Issue Likely To Follow Teva To 1st Circ.
• Mich. Senate Pushes Drugmaker Immunity Repeal Forward
• MVP: Paul Weiss' Krishna Veeraraghavan
• Icahn Goes After Illumina's Board In Del. Chancery Court
• Abortion Foes Ask For Full Review Or Nothing In Drug Appeal
• Community Pharmacist Group Lawyers Up To Take On PBMs
• Express Scripts Urges 9th Circ.: Keep Insulin Suit In Fed Court
• Pfizer To Pay $2M In Back Wages To Women Under DOL Deal
• FDA Softens Enforcement Of Blood Donation Rules
• NJ County Says Feds Rushed Flawed Ocean Wind 1 Approvals
• Walgreens Fights Crowell Bid To Ax Suit Over Humana Award
• Thermo Fisher To Acquire Sweden's Olink In $3.1B Deal
• Stem Cell Research Biz Loses $7M Atty Fee Bid In Patent Fight
• Sterigenics To Pay $35M To End Atlanta Suits Ahead Of Trial
• Considerations And Calculations For DOJ Clawback Program
• MVP: Paul Hastings' Eric Dittmann
• Biotech Investors Get Final Nod For $1.4M Settlement
• Catching Up With Delaware's Chancery Court
• US, EU Industry Groups Call For Openness In Summit Talks
• J&J's DePuy Wins Seattle Trial Of Faulty Knee Implant Claims
• Insurer Says Faulty Dehumidifier Caused $900K Fire Damage
• Arthrex Prevails In PTAB Challenges To Joint Repair Patents
• Verrill Dana Adds Seasoned Health Care Lawyer
• Lyra Taps New CLO As It Looks To Launch Nasal Implants
• Biotech Firm, Energy Producer Eye IPOs Totaling $450M
• SEC's Life Sciences Actions Utilize Novel Tools And Theories
• Smart Medical Device Maker Inks $60M SPAC Merger
• Feds Rip Ex-NJ Firefighter's $50M Drug Fraud Sentence Fight
• What Case Trends Reveal About Life Sciences Results At ITC
• ESG Around The World: Japan
• Investors In Maker Of Failed COVID Test Want Class Certified
• Pharma Co. Investors Want Docs On Post-Merger Payments
• How And Why Your Firm Should Implement Fixed-Fee Billing
• FDA Sends Proposed Menthol Ban To White House
• Supreme Court Won't Hear Milk Vitamin Patent Eligibility Case
• Womble Bond Brings On IP Team From Dentons In San Diego
• Munger Tolles Faces DQ Bid In GenapSys' Paul Hastings Suit
• PTAB Backs Edwards In Colibri Heart Valve Patent Challenge
• MVP: Davis Polk's David Bauer
• Potential Broader Effects Of FDA's Lab-Developed Test Rule
• Ex-FDA Regulatory Atty Joins Faegre Drinker In DC
• Rite Aid Taps Into DIP Loans, Sets Fast Ch. 11 Sale Schedule
• Kirkland's Jim Hurst Returns After Stint Away From Law
• DOJ Inks Settlement With Fla. Doc In Fentanyl Kickback Case
• Cancer Co. Seeks Ch. 7 Conversion Before Money Runs Out
• Pharma Supplier Says Ex-Sales Chief Broke Noncompete
• Pot License Denial Isn't 'Contested Case,' Ga. Panel Says
• AMA, Women's Clinic Drop ND 'Abortion Reversal' Challenge
• Supreme Court Deluged With Calls To Hear Abortion Pill Battle
• Calif. Atty Gets 6 Years For Selling $157M Of Unlicensed Drugs
• Pharma Co. RevitaLid Can Tap Part Of $17.5M Ch. 11 Funding
• 11th Circ. Revives Prisoner's Claims He Never Got Hep C Meds
• Attys Can't Contest Rule They Helped Revise, Panel Says
• Monkey Vet Says He Was Fired For Euthanasia Attempt Report
• Humana Beats Walgreens' Claims Over Crowell & Moring
• REIT Doesn't Owe LA Fitness Rent Refund, Panel Says
• Judicial Independence Needs Defense Amid Political Threats
• 2 New Ways FDA Is Changing Lab-Developed Test Regulation
• UK Litigation Roundup: Here's What You Missed In London
• FDI Considerations For UK Venture Capital Transactions
• Fed. Circ. Backs PTAB's Refusal To Invalidate Polymer IP
• Sorrento Seeks Quick Timeline On Process For Ch. 11 Plan
• Ex-Stimwave CEO Can't Toss Fraud Indictment
• Why Talc Claimants' Experts Should Fear New Jersey Courts
• Fed. Circ. Warned USPTO Ruling Threatens Antibody Patents
• Barnes & Thornburg Adds 2 Health Care Finance Attorneys
• GSK Unit Urges Chancery To Save Nebraska Patent Suit
• Eli Lilly Continues Migraine IP Wins Over Teva With PTAB Ax
• Okla. Pharmacy Owner Padded Pockets in Prescription Scam
• How Life Sciences Cos. Can Prevent Securities Class Actions
• How Law Firms Can Use Account-Based Marketing Strategies
• FDA Orders RJ Reynolds Flavored E-Cigs Off Market
• 11 Ways Senate Bill Would Alter PTAB Practice
• Chancery Rejects DMK Investor's Bid To Bar Annual Meeting
• Ill. Judge OKs Deal Over False Pharmacy Board Exam Failures
• Pharma Biz Says Fox Rothschild Atty Gave Secrets To Rival
• J&J Talc Unit Blasts $1.3M Ch. 11 Fee Claims By Talc Tort Firms
• Ill. Panel Won't Revive Nurse's Suit Over Hospital Vax Policy
• Navigating Over-The-Counter Product Ads After FTC Warning
• Swedish Medical Device Maker Buys US Biz For $320M
• RVL Pharma Units Hit Ch. 11 In Del. With Lender Handoff Plan
• EU Orders Illumina To Sell Off Grail
• 1st Circ. Resurrects Investors' Fraud Claim Against Biogen
• DNA Sequencing Patent Survives Guardant PTAB Challenge
• Investors Alleging $51M Loss To Lead Pharma Co. Suit
• Leaders of Drug Co. Hurt Stock With Lies, Suit Says
• Amyris Junior Creditors Waived Ch. 11 DIP Lien Protection
• FDA Launches New Digital Health Advisory Committee
• A Reminder For Drug Cos. To Confirm Orange Book Listings
• Split 9th Circ. Won't Revive IRhythm Securities Fraud Suit
• Strategic Succession Planning At Law Firms Is Crucial
• Sorrento To Sell JV Stake For $20M In 'Urgent' Bid For Cash
• Think Tanks Fight Dismissal Of $39B Debt Relief Challenge
• 2 Firms To Lead Investor Suit Over Myovant-Sumitomo Deal
• What An NCAA Drug Test Change Could Mean For Cannabis
• Pfizer Agrees To Shell Out $50M To Exit EpiPen Antitrust Suit
• Judge Mostly Clears Ex-Nestle Skin Biz In Dummy Head Fight
• Imaging Company To Pay $85M Over Doctor Kickback Scheme
• Adamis Investor Seeks Chancery Order To Block Board Vote
• Arrayit Exec Rips 15-Year Bid For COVID Fraud, Seeks 4 Years
• Medtech Co. Haemonetics Inks $253M Deal To Buy OpSens
• Florida Man Convicted In $67M Medicare Genetic Test Scam
• Fla. High Court To Review Abortion Rights Ballot Measure
• Calif. Gov. Vetoes Psychedelics Decriminalization Bill
• Consumer Suit Over Anti-Aging Supplements Moved To Utah
• FDA's Lab-Developed Test Rule Faces High Hurdles
• Catching Up With Delaware's Chancery Court
• Calif. Gov. Signs Law To Require Prescription Error Reporting
• Email Flub In Opioid MDL No Basis For Master's Removal
• Lipitor Hearing Punted As Ranbaxy Counsel 'Trapped' In Israel
• Justices Could Use Purdue To Resolve Related Circuit Split
• High Court Won't Hear Appeal Over FDA's E-Cig Denial
• Tech Firm Hit With Wage Suit Over 'Retroactive' Layoffs
• Cooley Adds Foley & Lardner Life Sciences Atty In San Diego
• Mapping Big Pharma's Blitz On Medicare Drug Price Talks
• Pharma Experts See Split On Effect Of Drug Price Negotiations
• Cooley Attys Savor Amgen-Horizon Close After FTC Battle
• J&J Unit Wants To Slash $27M Fees For Talc Claim Lawyers
• Gordon & Rees Boosts Its New Mexico Footprint
• DEA Issues 2nd Extension Of Telehealth Prescription Rule
• FDA Not Happy With Status Of Philips CPAP Recall
• FTC's Health Co. Suit Indicates Agency's Private Equity Focus
• Walgreens Sold 'Wholly Ineffective' Decongestants, Suit Says
• 2 Firms To Rep BioXcel Investors In Suit Against AI Drugmaker
• 'Lead Compound' Rule For Drug Patents Leads Courts Astray
• What Marijuana Status Change Would Mean For Industry
• Don't Miss It: Skadden, Latham Lead Hot Deals
• IP Forecast: Novartis To Fight Antitrust Row Over Drug Patent
• Biotech Co. Drops MRNA Patent Suit Against Pfizer, BioNTech
• Pharma Cos. Form Coalition To Fight FTC Merger Approach
• Women's Health Care Co. Raises $34M In Series B Round
• HHS Wants Quick Review Of Research Misconduct Allegations
• Top 4 Antitrust Enforcement Issues In Health Care Today
• Biologics Co. Execs Hit With Suit Over Revenue Controls
• 6 Lessons From Direct Selling Industry's Win Over FTC
• Calif. Climate Disclosure Bills Promise Challenges For Cos.
• Nurse Says OT Claims Don't Mimic Those In State Court Suit
• Maximizing Law Firm Profitability In Uncertain Times
• The Patent Eligibility Restoration Act Merits Deliberation
• Amyris Says $190M Ch. 11 Loan Should Get Senior Lien
• Justices Urged To Halt All In-House Cases Until Congress Acts
• Never Mind: Ozempic Patents Not Fully In The Clear At PTAB
• Zymergen Files Liquidation Plan As Ch. 11 Case Begins In Del.
• Fla. Jury Finds 2 Guilty In $93M Medicare Home Health Scam
• States Back Off Bid To Block Sandoz Spinoff In Antitrust Case
• Covington Brings On Ex-Mintz Capital Markets Pro In NY
• FDA Floats Advice For Developing Stimulant Addiction Drugs
• Ex-Eli Lilly Worker Settles Whistleblower Suit
• 8 Chinese Firms Indicted For Shipping Fentanyl Chemicals
• Teva Urges Court To Block Colo. EpiPen Access Program
• Chubb Unit, Wholesaler Close To Settling Opioid Coverage Row
• Mintz, Fenwick Mold Deal For $1B Life Sciences Tools Co.
• Lawmakers Bash UnitedHealth's M&A Tactics In Letter To DOJ
• Trending At The PTAB: Changes To Director Review, Hearings
• Major Drugmakers Set To Negotiate Medicare Drug Prices
• 11th. Circ. Told That Fla. Pelvic Mesh Suit Was Time-Barred
• LabCorp Hit With Meal Breaks, OT Class Action In Wash.
• Novo Nordisk Dodges PTAB Review On Lucrative Ozempic IP
• Colo. Woman Sues Prosthetic Co. Alleging Hip Implant Defect
• NJ Appeals Court Reverses $224M Talc Verdict Against J&J
• Justices Won't Hear Ex-MLB Player's Substance Ban Case
• Crowell Aims To Sink Walgreens Suit Over Humana Conflict
• 7 Common Compliance Pitfalls For Multistate Pharmacies
• Kirkland, Skadden Lead Eli Lilly's $1.4B Point Biopharma Buy
• AstraZeneca Inks $425M Deal To End Acid-Reflux Drug Claims
• Virginia Attorney's Office Reaches Nearly $1M FCA Settlement
• Novo Nordisk Joins Fight With HHS Over Drug Price Talks
• NuVasive Grills Ex-Exec On Jump To Competitor
• High Court Won't Review Abortion Foes' Bid In Video Case
• Sutter Health Emails Reveal Billing Confusion In $519M Trial
• Vitamin Co. Can't Escape 'Natural' Supplement False Ad Suit
• Genomic Health To Pay $32.5M In Medicare Billing FCA Deal
• Drug Co. Investors Settle Clinical Trial Suit For $2.3M
• Uncertainty Still Looms For IPOs Despite Shutdown Reprieve
• Shkreli-Tied Vyera Pharmaceuticals Gets Ch. 11 Plan OK
• 5th Circ. Ruling Reminds Attys That CBP Can Search Devices
• High Court Seeks SG Opinion In Pharma Terror-Funding Suit
• FDA's Drug Software Draft Guidance Raises New Questions
• Insurer Must Face Claim In Crowell & Moring Imbroglio
• Another Alice Appeal Bites The Dust At High Court
• Finnegan Rehires 2 IP Attys In Boston, DC
• Catching Up With Delaware's Chancery Court
• ESG Around The World: European Union
• Minerals Technologies Puts Barretts Talc Unit Into Bankruptcy
• High Court Turns Away Colgate's Challenge To ERISA Case
• Justices Reject Plea To Ease FCA Kickback Standard
• Supreme Court Rejects Diagnostics IP Challenge
• Law360 MVP Awards Go To 171 Attys At 76 Firms
• Planned Parenthood Gets Halt Of NC Abortion Limits, For Now